+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Minimal residual disease in acute myeloid leukemia correlates with P-glycoprotein function but not with multidrug resistance protein function at diagnosis



Minimal residual disease in acute myeloid leukemia correlates with P-glycoprotein function but not with multidrug resistance protein function at diagnosis



Leukemia 17(3): 663




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035314274

Download citation: RISBibTeXText


Related references

High P-Glycoprotein Function but Not Multidrug Resistance Protein Function at Diagnosis Correlates with Minimal Residual Disease in Acute Myeloid Leukemia. Blood 100(11): Abstract No 1244, 2002

Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. Haematologica 88(2): 134-147, 2003

Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia. Leukemia 15(10): 1554-1563, 2001

Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia. Leukemia 15(10): 1554-1563, 2001

Function of drug resistance proteins during therapy, in minimal residual disease and at relapse in acute myeloid leukemia. Blood 98(11 Part 1): 308a, 2001

The Pipecolinate Derivatives VX-710 and VX-853 Are Effective Modulators of Drug Efflux Mediated by the Multidrug Resistance Proteins P-Glycoprotein, Multidrug Resistance Protein and Breast Cancer Resistance Protein in Acute Myeloid Leukemia Cells. Blood 100(11): Abstract No 245, 2002

Minimal residual disease in acute myeloid leukemia is predicted by an apoptosis-resistant protein profile at diagnosis. Clinical Cancer Research 11(7): 2540-2546, 2005

Evaluation of the clinical relevance of the expression and function of P-glycoprotein, multidrug resistance protein and lung resistance protein in patients with primary acute myelogenous leukemia. Leukemia Research 26(2): 143-154, 2002

Evaluation of the clinical relevance of the expression and function of P-glycoprotein , multidrug resistance-associated protein and lung resistance protein in patients with primary acute myelogenous leukemia. Blood 92(10 Suppl. 1 Part 1-2): 389A, 1998

Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status. Leukemia 11(7): 1073-1077, 1997

Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: Impact of antibodies, sample source and disease status. Leukemia 11(7): 1073-1077, 1997

The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. Investigational new Drugs 25(2): 115-122, 2007

The coexpression of at least two proteins including P-glycoprotein , the multidrug-resistance related protein , bcl-2, mutant p53 and heat-shock protein 27 in myeloid blasts is more predictive for treatment failure and overall survival in patients with acute myeloid leukemia than PgP alone. Proceedings of the American Association for Cancer Research Annual Meeting 38: 388, 1997

Prospective study of P-glycoprotein, multidrug resistance associated protein and lung resistance related protein expression in acute myeloid leukemia treated with the JALSG-AML95 protocol. Blood 102(11): 605a, 2003

Multifactorial resistance in patients with acute myeloid leukemia (AML): Coexpression of P-glycoprotein, the multidrug-resistance related protein (MRP) as well as heat shock proteins. Journal of Cancer Research and Clinical Oncology 121(1 Suppl.): A46-0, 1995